Nebido (Testosterone Undecanoate)

Testosterone undecanoate, the active ingredient in Nebido, is an androgen; anabolic steroid presented as an injectable solution for intramuscular injection use. It treats male hypogonadism, testosterone deficiency, and delayed puberty in males.

GNH USA supplies Nebido as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebido is used in androgen‑related disorders to restore physiological testosterone levels.

Male hypogonadism: improves symptoms such as low libido, fatigue and loss of muscle mass. Testosterone deficiency: normalises serum testosterone and supports anabolic processes. Delayed puberty in males: promotes development of secondary sexual characteristics.

Nebido may cause a range of adverse reactions, some of which are more frequent than others.

Common Side Effects: - Acne or oily skin. - Increased red blood cell count (erythrocytosis). - Fluid retention or peripheral edema. - Elevated prostate‑specific antigen (PSA) levels. - Mood swings or irritability. - Decreased sperm production.

Serious or Rare Side Effects: - Thromboembolic events such as deep‑vein thrombosis. - Cardiovascular complications including myocardial infarction. - Severe allergic reactions (anaphylaxis, angioedema). - Progression of prostate cancer. - Significant liver enzyme elevation. - Sleep‑apnoea worsening.

Before initiating Nebido therapy, several safety considerations should be addressed.

Monitor hematocrit: perform regular blood counts to detect erythrocytosis. Assess cardiovascular risk: evaluate history of heart disease or stroke. Screen for prostate disease: conduct PSA testing and digital rectal exam. Avoid use in known hypersensitivity: discontinue if allergic reaction occurs. Use caution in hepatic impairment: monitor liver function tests. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nebido can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Warfarin: may increase anticoagulant effect and bleeding risk. - Insulin or oral hypoglycemics: can affect glucose control, requiring dose adjustments. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise testosterone levels.

Moderate Interactions (Monitor Closely): - Antihypertensives: testosterone may reduce their blood‑pressure‑lowering effect. - Glucocorticoids: combined use can exacerbate fluid retention. - Estrogen therapy: may antagonise the intended androgenic effects.